Jefferies Initiates Coverage On Relmada Therapeutics with Buy Rating, Announces Price Target of $9
Benzinga Newsdesk 10 months ago
NewsPrice TargetInitiationAnalyst Ratings
Jefferies analyst Farzin Haque initiates coverage on Relmada Therapeutics (NASDAQ:RLMD) with a Buy rating and announces Price Target of $9.
Jefferies analyst Farzin Haque initiates coverage on Relmada Therapeutics (NASDAQ:RLMD) with a Buy rating and announces Price Target of $9.